Friday, January 25, 2013

U Michigan gets birth defects grant


U Michigan gets birth defects grant
By DrBicuspid Staff
December 24, 2008 -- Dental school graduates can study cleft lips and palates and other craniofacial anomalies at the University of Michigan thanks to a new $750,000 fellowship, according to a report in the Ann Arbor News.
The money comes from the Coghlan Family Foundation, which donated $500,000, and the university itself, which added $250,000 to the fund through U-M President Mary Sue Coleman's Donor Challenge program, the newspaper reported.
"In the state of Michigan, we have about 3,000 children born with a craniofacial anomaly or birth defect," Katherine Kelly, D.D.S., M.S., an adjunct professor, told the newspaper. "We only have 300 orthodontists in the state, and a fair number of those are elderly and retiring and didn't receive this training."
Application submission opens next summer, and the one-year fellowship will be awarded to one dental school resident each year.

Wednesday, January 23, 2013

Hoya ConBio launches all-tissue erbium laser


Hoya ConBio launches all-tissue erbium laser
By DrBicuspid Staff
November 24, 2008 -- Hoya ConBio has launched the VersaWave Specialty Er:YAG all-tissue dental laser, according to a company press release.
Featuring a wide range of power settings, the VersaWave Specialty allows for treatment of all phases of soft- or hard-tissue dentistry, the company said. The system is designed for general and aesthetic dentists, as well specialists in periodontics, endodontics, prosthodontics, and pediatrics.
The laser will debut at the 2008 Greater New York Dental Meeting later this month.

Dentsply to take majority interest in Italian firm


Dentsply to take majority interest in Italian firm
By DrBicuspid Staff
November 24, 2008 -- Dentsply International has entered into a definitive agreement with the shareholders of Zhermack of Badia Polesine, Italy, to acquire a majority interest (60%) in the European firm, according to the company. Terms of the deal were not disclosed.
As part of the agreement, the two founders of Zhermack will retain "significant ownership" and continue to manage the business.
Zhermack is a producer of dental impression materials and lab equipment and sells products in more than 100 countries, with an emphasis on Europe, Latin America, Asia, and the Commonwealth of Independent States. The company has manufacturing facilities in Italy and Poland.
"We believe that our polymer-based expertise can contribute to Dentsply's R&D efforts, and as partners, we can continue developing innovative products for the dental profession," said Tiziano Busin, Zhermack's president and founder, in a press release.

Studies show Nomad portable x-ray system safe


Studies show Nomad portable x-ray system safe
By Kathy Kincade, Editor in Chief
November 14, 2008 -- It may look like something out of a sci-fi movie, but the Nomad portable x-ray system from Aribex is taking the notion of "ray gun" to a whole new level, especially in dentistry.
Introducing CEREC® Omnicam.The most perfect CAD/CAM camera ever
SironaSlim, elegant design for easier intraoral access, fast photorealistic color imaging, and powderless convenience make the new CEREC Omnicam the most precise, easy-to-use CAD/CAM
camera ever.
Five years ago, the idea of a handheld, battery-powered, intraoral x-ray device was little more than that -- a nifty idea. Portable x-ray systems have been around for years, but they can be cumbersome and restrictive. Dentists operating in humanitarian or forensic field situations, for example, need compact, lightweight, and, most important, truly portable instruments -- that is, untethered from wall mounts and wall sockets.
Enter Aribex, a company founded in 2003 to develop new forms of x-ray technologies for medical and industrial applications. Founder and president Clark Turner, Ph.D., says he got the idea for the company's flagship product, the Nomad, from conversations with his dentist.
"I was working on miniature x-ray tubes, and he was going to Russia to do humanitarian work," Turner said in an interview with DrBicuspid.com. "He was intrigued with the idea of mini x-ray tubes and said there was a need for a battery-powered x-ray device in dentistry. Everything at the time was 20 lbs and had to be plugged into the wall and set on a tripod."
By 2005, Turner had produced a prototype of the Nomad, a handheld intraoral x-ray system that looks much like a construction drill but operates like a conventional wall-mounted radiography system. It can accommodate digital sensors or film and utilizes a 14.4-volt nickel-cadmium battery that provides up to 700 exposures on a single charge. The Nomad is designed for general-purpose dental use and is particularly helpful when working with children, sedated patients, or special needs patients. In operation, the technician stands next to the patient, positions the device, and takes the radiograph. This saves time, shortens the time the patient has to sit still with film or a sensor in their mouth, and reduces retakes, according to the company.
The Nomad portable x-ray system by Aribex. All images courtesy of Aribex.
"There are certain procedures where this has a particular advantage, such as endodontic procedures where the practitioner has a drill or file in the tooth and they don't want to move away from the patient," Turner said. "The other really good application is oral surgery, where the rooms are typically too big to make a wall-mount system practical so the oral surgeons use mobile x-ray systems. It was also designed for out-of-office applications; my dentist uses it every Friday at the homeless shelter where he does volunteer work."
Aribex gained FDA clearance for the Nomad in July 2005 and introduced it commercially in 2006, selling for around $7,000. While the device is a little pricier than a wall-mount system, which typically sells for around $4,000, Turner points out that with the Nomad, if you have multiple operatories, you don't need multiple wall-mounted systems. It also eliminates the construction costs associated with reinforcing walls and installing electrical hookups.
"The FDA has a performance standard for intraoral x-ray machines, so as long as you meet these performance standards, it is pretty easy to get approved," Turner said. "It's all about repeatability of the dose and accuracy of the timers. And the FDA regulations don't require it to be mounted on a wall."
Radiation exposure
Unfortunately for Aribex, most state dental boards are stricter in their regulation of dental x-ray systems. The company has spent the last three years going state by state to gain the necessary clearances to allow dentists to use the Nomad. So far 37 have said OK, according to Turner.
The very thing that makes the Nomad so unique -- the ability to have the operator stay in the room, next to the patient, while x-rays are taken -- is also the source of the biggest concern for many state boards: radiation exposure. Thus Aribex has conducted numerous studies to show that the Nomad is safe for users and patients alike, Turner said. Authors of a paper published in Dentomaxillofacial Radiology (February 2008, Vol. 37:2, pp. 109-112), for example, concluded that "Our data have shown that the Nomad presents risks that are no greater than with standard dental radiography units to the patient or operator and the measured doses are well below recommended levels."
The key to making the device safe is the proprietary lead-filled acrylic backscatter shield attached at the end of the cone, Turner said. Radiation studies conducted by Aribex found that in a "worst case" situation -- taking 60 exposures per hour at a maximum exposure of 0.99 seconds each -- an operator has the potential to receive 3.6 mR/hr leakage at the hand. The maximum allowable radiation leakage, per FDA regulations, is 100 mR/hr.
Still, some state dental boards remain unconvinced. In addition, an evaluation of the Nomad conducted by the U.S. Air Force Dental Evaluation and Consultation Service in 2006 noted that "with some patient positions the backscatter shield count not provide the operator with maximum shielding."
"There are some concerns about operator safety, as evidenced by the number of states that have not approved or restrictively approved the use of the Nomad," said Edwin Parks, D.M.D., M.S., the director of dental radiology at the Indiana University School of Dentistry in Indianapolis. "We had a health physicist assess the Nomad for scatter and found minimal exposure to the operator. We sent the information to the state office that deals with radiologic health, and they still chose not to approve the use of the Nomad in the state of Indiana."
Likewise, research conducted by Robert Danforth, D.D.S., an associate professor of radiology at the University of Nevada Las Vegas (UNLV), and Ed Herschaft, D.D.S., M.A., a professor of biomedical sciences at UNLV, for the radiology section of the state of Nevada found that "when used as shown in the manufacturer's brochures, the protection shield provides appropriate operator protection."
However, if the operator is positioned in an atypical position, a small dose to the reproductive area was detected, Dr. Danforth said. "This is the result of not always being totally within the 'safe zone' of the protection shield," he stated in an e-mail to DrBicuspid.com. "Personnel and patients in adjacent cubicles were not at risk, but assistants/personnel directly involved should not stand within 6 feet of the primary beam pathway." Scatter dose off of the patient and to adjacent areas was negligible at the 6-foot range from the patient's head and generally corresponded to the direction of the primary beam, he added.
Blurring?
The very thing that protects users from radiation exposure -- the lead-based backscatter shield -- also makes the Nomad heavier than some prefer, prompting some speculation about image quality. While customers are generally positive about the handheld, tetherless concept of the Nomad, there have been complaints that, at 8.5 lb, the initial system was tiring to use, according to Turner. The company thus reworked the design -- eliminating the lead lining in the collimator and replacing it with silicon infused with heavy inert nontoxic metals -- and launched a lighter version, the 5.5 lb Nomad Pro, earlier this year.
"My biggest concern regarding the Nomad is the weight of the product," Dr. Parks said. "The new one is a lot lighter than the original model, but it is still heavy if you are taking more than a couple of images. Other than that, I think the Nomad has a number of useful applications for dentistry."
With regard to image quality, Turner said that blurring isn't possible with the short exposure time: 0.2-0.3 seconds. Also, the Nomad uses the smallest focal spot available (0.4 mm), which Turner said further improves the image quality.
Dr. Danforth noted that the image quality can vary depending on what type of film is used. The UNLV dosimetry studies involving digital sensors and F-speed film resulted in image quality "well within [the] acceptable range and not blurred, as some uninformed individuals want to imply," he told DrBicuspid.com. Ultra D-speed film, however, requires a longer exposure and could be subject to some motion artifact, he added.
"In general, I have favorable views concerning the newer version of the Aribex Nomad for use in making a limited number of exposures, such as bitewings and occasional periapicals," Allan Farman, B.D.S., M.B.A., Ph.D., D.Sc., a professor of radiology at the University of Louisville of Kentucky, stated in an e-mail to DrBicuspid.com. "I was not so impressed by the older version, as the battery was quite heavy and use could tire the operator, which in turn could lead to motion unsharpness. The newer version uses much lighter batteries and is a vast improvement."
Dr. Farman also noted that, while the Nomad is well-suited to operative radiology in which the baseline is a digital panoramic radiograph, he does not see the Nomad as a sensible alternative for making the traditional full-mouth intraoral x-ray series as a baseline on new patients or for periodic review.
"However, I am not a protagonist of the full-mouth intraoral survey, given improved image quality with the newer panoramic systems," he added.

Ameritas offers cosmetic dental benefits


Ameritas offers cosmetic dental benefits
By DrBicuspid Staff
November 14, 2008 -- Ameritas Group will now cover professional tooth bleaching and tooth-color composite fillings on molars, the company announced.
"Our bleaching benefit offers upper and lower arch bleaching every two years, in addition to coverage for two types of single-tooth bleaching," stated Karen Gustin, vice president of group marketing and managed care for Ameritas Group, in a press release. "By offering composites on molars, along with the composite coverage we already offer on bicuspids and the smile line, patients can enjoy dental fillings that appear all natural."

Study: Implants need more post-op care than root canals


Study: Implants need more post-op care than root canals
By DrBicuspid Staff
November 13, 2008 -- A new study published in the November issue of the Journal of Endodontics addresses the growing controversy among dental health professionals regarding the best course of treatment when evaluating between a root canal or dental implant procedure, according to a press release from the American Association of Endodontists (AAE).
Researchers evaluated the success and failure rates of teeth treated with a root canal (endodontically treated teeth) or extracted and replaced with a dental implant. While the findings concluded that the success rate of each treatment was similar, the data showed that significantly more dental implants required additional treatment or surgical intervention after the procedure compared to endodontically treated teeth (12.4% versus 1.3%, respectively) (JOE, November 2008, Vol. 34:11, pp. 1302-1305).
"Many dental professionals today are faced with the dilemma of whether root canal treatment or dental implants are the best option for their patients," said lead investigator James Porter Hannahan, D.M.D., of the University of Alabama at Birmingham. "While the success of both procedures is similar, saving the natural tooth through a root canal rarely requires follow-up treatment and generally lasts a lifetime; implants, on the other hand, have more postoperative complications and higher long-term failure rates."
Dr. Hannahan and his colleagues evaluated patient charts of 129 dental implants for an average of 36 months (range, 15-57 months) and of 143 endodontically treated teeth for an average 22 months (range, 18-59 months). Implant data were collected from a periodontic group practice, and root canal data were collected from an endodontic group practice. Researchers placed each procedure into one of three categories: success, uncertain, and failure. Success was defined as radiographic evidence that the implant or treated tooth was still present in the mouth and there were no signs or symptoms requiring intervention during the follow-up treatment period. Failures were defined as the removal of the implant or tooth.
The investigators found two failures of the 129 dental implants for a success rate of 98.4%. They also found only one failure of the 143 endodontic treatments for a success rate of 99.3%. These results were not statistically significant (p = 0.56) with the Fisher exact test, a statistical significance test. However, 12.4% of the dental implants required additional interventions, whereas only 1.3% of the endodontically treated teeth required additional interventions, which was statistically significant (p = 0.0003).
"Considering these results in light of the growing body of evidence on the impact of oral health on overall health, it is imperative for dental professionals to partner with endodontists who have advanced training in examining whether a natural tooth can be saved through root canal treatment," said Dr. Louis Rossman, an endodontist and president of the AAE. "While implants may be an appropriate solution for people with missing teeth, endodontic treatment should be the first choice for restoring a compromised tooth."

Tuesday, January 22, 2013

Study questions effectiveness of oral cancer detection devices


Study questions effectiveness of oral cancer detection devices
By Rabia Mughal, Contributing Editor
September 30, 2008 -- Clinicians should rely on oral exams, specialty referrals, and tissue biopsies to best diagnose premalignant and malignant oral lesions because there isn't enough data to prove that adjunctive cancer detection devices are effective in a general practice setting, according to a recent study in the Journal of the American Dental Association(JADA, July 2008, Vol. 138:7, pp. 896-905).
There is an ongoing debate in the dental community about the utility of these devices in the early detection of oral cancer. But the manufacturers of these products stand by them and contend that the JADA study is too limited in its scope.
In the JADA literature review, the authors searched for articles on PubMed, ISI Web of Science, and the Cochrane Library from January 1966 through February 2008 that evaluated the effectiveness of toluidine blue (TB), ViziLite Plus with TBlue, ViziLite, Microlux DL, Orascoptic DK, VELscope, and the OralCDx brush biopsy. Ultimately, they short-listed 23 studies that met their criteria.
In particular, they included studies that reported histologic confirmation of lesions identified by adjunctive techniques, or those that allowed calculation of the test's accuracy compared with tissue biopsy.
The researchers looked at study design, sampling, and characteristics of the study group; interventions and reported lesion diagnostic outcomes; information about the clinical setting (mucosal disease or cancer center clinic or a general practice); and subjects' presumed oral cancer risk.
"We gave each article a summary quality score by means of assessing a priori identified important attributes of the study that may have led to bias in interpretation of results," the authors wrote.
ViziLite Plus with TBlue
The authors looked at three studies that examined ViziLite and reported that its sensitivity was consistently at 100%. However, the authors noted, all three studies involved patients with previously visualized mucosal lesions. The specificity ranged from 0% to 14%. The positive predictive value (PPV) was 18% to 80%, and the negative predictive value (NPV) ranged from 0% to 100%.
No longer available as a standalone device, ViziLite is only available as a kit with blue phenothiazine dye (TBlue). Two studies assessed ViziLite Plus with TBlue.
"The investigators found that ViziLite enhanced visual lesion characteristics in approximately 60% of lesions, identified all lesions previously identified with standard light and identified no additional lesions," the authors wrote. "The addition of TB application to the chemiluminescence enhanced visual examination ... improved the specificity and PPV and increased the NPV to 100%."
Zila Pharmaceuticals, the company that manufactures and markets ViziLite, took exception to some of the study's findings, however. ViziLite's efficacy in identifying suspicious lesions that are missed during visual examination was not accurately reported in the article because the authors used only manuscripts reporting previously identified visual lesions, Mark Bride, D.D.S., Zila's vice president of medical and clinical affairs, told DrBicuspid.
"The ViziLite studies eliminated from consideration were conducted by mucosal disease specialists and thus, per their [the authors] criteria, considered lower quality studies," he noted. "This makes little sense in that the outcomes of those studies demonstrated an improvement in the net yield of lesions suspicious for precancer or cancer with the inclusion of chemiluminescent examination. The article determined that these results are not translatable to a general practitioner in a general screening population. This conclusion is disconcerting and should have no bearing on determining study quality."
Dr. Bride also pointed out that, since Zila's only product is ViziLite Plus with TBlue, reporting on the performance of individual components does not accurately represent the product.
"Unfortunately, by eliminating pertinent studies from the analysis for the purpose of comparing device outcomes to histologic (biopsy) outcomes, ViziLite Plus with TBlue was positioned as a diagnostic tool instead of a screening adjunct," he added.
VELscope
VELscope manufacturer LED Dental also said the study selection does not accurately represent its product.
The JADA study authors looked at two studies that assessed the VELscope. Both involved patients with known oral dysplasia or squamous cell carcinoma (SCCa) confirmed by biopsy.
"Compared with the sensitivity of histopathological examination in patients with identified high-grade dysplastic lesions and SCCa, the reported sensitivities of tissue autofluorescence with the VELscope technology as an adjunct to visual examination were 98% and 100%; specificity was 100% and 78%; PPVs were 100% and 66%; and NPVs were 86% and 100%, respectively," the authors wrote.
The VELscope is useful in assessing lesion margins in patients with oral premalignant and malignant lesions, the authors noted. No studies have been published on its effectiveness as a diagnostic adjunct in lower-risk populations or in patients seen by primary care providers.
"I believe it is a good exercise to see how the various oral cancer screening methods and technologies 'stack up' against this type of rigorous criteria," stated David Morgan, Ph.D., LED Dental's chief science officer, in an e-mail to DrBicuspid. "The bottom line is that none of them compare very well against this type of standard -- and this includes the conventional oral examination itself. Even biopsy with histopathological examination, the gold standard for diagnosis, has significant issues -- sampling problems and subjective rather than objective assessment criteria, which lead to less than ideal inter- and even intrapathologist variability."
Holding newer adjunctive techniques to this kind of standard -- prospective, randomized, controlled, community based multisite studies conducted by nonexpert clinicians on a general, low-risk population -- and recommending that clinicians not to use them because they don't measure up to this standard yet is misguided, he added. The VELscope is not a standalone diagnostic test, he stated.
"It is peculiar that there is concern about using technologies which, when used properly in combination with a conventional exam, help you see more things better, things you might have missed, sometimes things that might save somebody's life," Morgan noted.
OralCDx brush biopsy
The JADA study authors also looked at four studies involving the use of the OralCDx brush biopsy in detecting or diagnosing oral premalignant and malignant lesions. They concluded that, while the test has utility in detecting dysplastic changes in mucosal lesions, there is insufficient data to assess its utility in low-risk populations or clinically innocuous lesions.
Drore Eisen, M.D., D.D.S., medical director of OralCDx Laboratories, said that this finding is "clinically pointless."
"Using the same inclusion criteria that the authors applied to studies of OralCDx, the sensitivity of the scalpel biopsy for testing those nonsuspicious lesions, which are not subjected to scalpel biopsy, is certainly unknown," he said. "For the practicing general dentist, how suspicious an oral lesion may appear matters little, since all white and red tissue changes without a known cause require testing regardless of how suspicious they may appear, and OralCDx offers dentists the only noninvasive and accurate method of testing them."
The study authors stated that, based on the literature, the sensitivity of the OralCDx test varied from 71% to 100%, specificity varied from 27% to 94%, PPV ranged from 38% to 88%, and NPV ranged from 60% to 100%.
But in every comparative study in which the OralCDx brush and scalpel biopsy of a lesion are performed simultaneously and on the same tissue, a very high degree of agreement between these two biopsy techniques is always confirmed, Dr. Eisen said.
"In a recent study of 200 patients with oral leukoplakia, two scalpel biopsies taken of the same lesion agreed with each other only 56% of the time, and underdiagnosis from scalpel biopsy was noted in 29.5% of patients," he said. "Therefore, those studies quoted in the JADA paper, which reported some discrepancies between brush biopsy and scalpel biopsy results, are completely meaningless since in all of those studies the two biopsy samples were obtained by two different examiners and at widely different times."
The authors did not find any studies that met their criteria for the Microlux DL and Orascoptic DK systems.
The authors did not respond to repeated attempts to give them the opportunity to respond to the vendors' comments here.